NGL Fine-Chem Ltd - Stock Valuation and Financial Performance

BSE: 524774 | NSE: NGLFINE | Pharmaceuticals & Drugs | Small Cap

NGL Fine-Chem Share Price

2,080 -22.35 -1.06%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on NGL Fine-Chem

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

NGL Fine-Chem stock performance -

mw4me loader
P/E Ratio (SA):
35.67
Market Cap:
1,291.3 Cr.
52-wk low:
1,171
52-wk high:
2,425.1

Is NGL Fine-Chem Ltd an attractive stock to invest in?

1. Is NGL Fine-Chem Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that NGL Fine-Chem Ltd is a average quality company.

2. Is NGL Fine-Chem Ltd undervalued or overvalued?

The key valuation ratios of NGL Fine-Chem Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is NGL Fine-Chem Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of NGL Fine-Chem Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of NGL Fine-Chem:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
NGL Fine-Chem Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 16.5%18.5%23.9%21.1%14.1%18.1%9.7%37.2%26.2%8.7%-
Value Creation
Index
0.20.30.70.500.3-0.31.70.9-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 78.988.396.399.7114153152258319275306
Sales YoY Gr.-12%9%3.6%14%34.8%-0.7%69.7%23.4%-13.7%-
Adj EPS 8.111.318.522.918.62916.688.184.632.658.6
YoY Gr.-38.9%63.1%24.2%-18.9%56%-42.7%430%-4%-61.5%-
BVPS (₹) 39.753.171.696.2116.6149.1163.8251.6334.4365407.8
Adj Net
Profit
5711.414.211.517.910.354.552.320.136
Cash Flow from Ops. -0.37.58.49.922.48.919.626.615.831.9-
Debt/CF from Ops. -56.21.81.72.31.23.11.40.61.91-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 14.9%19.3%21.8%-13.7%
Adj EPS 16.7%11.9%25.1%-61.5%
BVPS28%25.6%30.6%9.2%
Share Price 55.9% 34.7% 8.6% 67.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
22.624.429.627.317.521.810.642.428.99.315.2
Op. Profit
Mgn %
14.316.922.825.61921.115.229.820.710.413.8
Net Profit
Mgn %
6.47.911.814.210.111.76.821.116.47.311.8
Debt to
Equity
0.70.40.30.40.40.30.30.10.20.1-
Working Cap
Days
138152160187198167184132166216103
Cash Conv.
Cycle
62657481655579497410164

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 21.81%

Net Profit is growing at healthy rate in last 3 years 25.10%

Sales growth is good in last 4 quarters at 11.44%

Return on Equity has declined versus last 3 years average to 15.20%

Latest Financials - NGL Fine-Chem Ltd.

Standalone Consolidated
TTM EPS (₹) 58.6 62.1
TTM Sales (₹ Cr.) 306 313
BVPS (₹.) 407.8 407.3
Reserves (₹ Cr.) 249 249
P/BV 5.13 5.13
PE 35.67 33.68
From the Market
52 Week Low / High (₹) 1171.00 / 2425.10
All Time Low / High (₹) 0.40 / 3789.45
Market Cap (₹ Cr.) 1,291
Equity (₹ Cr.) 3.1
Face Value (₹) 5
Industry PE 48.2

Management X-Ray of NGL Fine-Chem:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of NGL Fine-Chem

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales798896100114153152258319275
Operating Expenses 6873747492121131181253246
Manufacturing Costs13131315182227335050
Material Costs40424138466365103148140
Employee Cost 891114182124273334
Other Costs 79108101516192223
Operating Profit 11152225223221776629
Operating Profit Margin (%) 14.3%16.9%22.8%25.5%19.0%21.1%13.7%29.8%20.7%10.4%
Other Income 00013439138
Interest 2221233222
Depreciation 2333567788
Exceptional Items -1200000000
Profit Before Tax 7131823182814766927
Tax 256857421176
Profit After Tax 581115132011555220
PAT Margin (%) 5.7%9.4%11.8%14.9%11.1%13.1%7.0%21.5%16.4%7.3%
Adjusted EPS (₹)7.313.518.524.120.532.617.289.884.632.6
Dividend Payout Ratio (%)0%0%0%0%0%5%10%2%2%5%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 253344597292101155207226
Share Capital 3333333333
Reserves 21304156698998152203222
Minority Interest0000000000
Debt15111320242323112730
Long Term Debt32091288632
Short Term Debt1110121111151552328
Trade Payables12171414241621273523
Others Liabilities 5571714181112109
Total Liabilities 566778111133149156206278288

Fixed Assets

Gross Block292938286474818592100
Accumulated Depreciation101113371320273341
Net Fixed Assets19172425566161585959
CWIP 012163001626
Investments 02366914333243
Inventories8121012171928385527
Trade Receivables24263230283326386565
Cash Equivalents 12224335113
Others Assets46420192523346054
Total Assets 566778111133149156206278288

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 0881022920271632
PBT 7131823182814766927
Adjustment 23335811376
Changes in Working Capital -7-4-6-84-19-2-32-436
Tax Paid -2-5-6-8-5-7-4-21-17-6
Cash Flow From Investing Activity -4-3-10-10-21-10-19-24-16-24
Capex -4-3-10-18-23-14-7-5-14-29
Net Investments 000100-4100
Others 000725-8-20-25
Cash Flow From Financing Activity 3-42000-1-1-1-1
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0-2-10000000
Interest Paid 0000000000
Dividend Paid 000000-1-1-1-1
Others 3-230000000
Net Cash Flow -11001-102-17
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)20.3329.0429.5928.7319.2224.5210.9743.2228.869.31
ROCE (%)22.2433.0337.1433.821.6827.6313.6551.934.7111.5
Asset Turnover Ratio1.651.571.441.130.951.0811.431.320.97
PAT to CFO Conversion(x)010.730.671.690.451.820.490.311.6
Working Capital Days
Receivable Days8495103107917271455986
Inventory Days39393937454256465354
Payable Days10211912312314511197746567

NGL Fine-Chem Ltd Stock News

NGL Fine-Chem Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of NGL Fine-Chem on 28-Mar-2024 16:01 is ₹2,080.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of NGL Fine-Chem stood at ₹1,291.3.
The latest P/E ratio of NGL Fine-Chem as of 28-Mar-2024 16:01 is 35.67.
The latest P/B ratio of NGL Fine-Chem as of 28-Mar-2024 16:01 is 5.13.
The 52-week high of NGL Fine-Chem is ₹2,425.1 and the 52-week low is ₹1,171.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of NGL Fine-Chem is ₹306.3 ( Cr.) .

About NGL Fine-Chem Ltd

NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.

Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.

Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.

It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.

NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.

Product range of the company includes:

Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:

  • Animal health
  • Human health
  • Intermediate- 4 Aminobenzamidine Dihydrochloride, 3 Aminobenzamidine Dihydrochloride, Ezetimibe Intermediates etc
  • Finished dosages form- Homidium Chloride Tablets, Diminazene Aceturate Granules

Achievements/ recognition

An ISO 9001:2000 accredited company

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.